MRNA Moderna, Inc.

NASDAQ
$63.32

Moderna, Inc. (MRNA) is expected to report earnings on October 30, 2026, before the market open. The consensus earnings estimate is a loss of $1.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.5% since its last earnings release on July 31, 2026.

Moderna Missed Expectations
Friday, July 31, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 30
Friday · Before Open
Earnings Whisper
-
vs ($1.38)
Rev est $920.13M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $59.03

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Moderna, Inc.

Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale.

Sector

Healthcare

Industry

Biotechnology